Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ LRRK2 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA116770
Description
The target sequence has 87% sequence homology with rat.
LRRK2 is a multidomain protein that includes a kinase domain, a GTPase domain, and a leucine-rich repeat (LRR) domain. Mutations in LRRK2 have been associated with Parkinson's disease. LRRK2 is a member of the leucine-rich repeat kinase family and encodes a protein with an ankryin repeat region, a leucine-rich repeat domain, a kinase domain, a DFG-like motif, a RAS domain, a GTPase domain, a MLK-like domain, and a WD40 domain. The protein is present largely in the cytoplasm but also associates with the mitochondrial outer membrane.
Specifications
| LRRK2 | |
| Polyclonal | |
| Unconjugated | |
| LRRK2 | |
| 4921513O20Rik; 9330188B09Rik; augmented in rheumatoid arthritis 17; AURA17; AW561911; BC 300-268; cI-46; D630001M17Rik; DARDARIN; DKFZp434H2111; FLJ45829; Gm927; leucine rich repeat kinase 2; leucine-rich repeat kinase 2; leucine-rich repeat serine/threonine-protein kinase 2; LRR kinase 2; LRRK 2; Lrrk2; LRRK-2; PARK8; RIPK7; ROCO2 | |
| Rabbit | |
| Antigen affinity chromatography | |
| RUO | |
| 120892, 535652, 66725 | |
| Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
| Liquid |
| Flow Cytometry, Immunohistochemistry (Frozen), Immunohistochemistry (Paraffin), Immunoprecipitation, Western Blot, Immunocytochemistry | |
| 1 mg/mL | |
| PBS with 0.02% sodium azide | |
| Q5S006, Q5S007 | |
| LRRK2 | |
| Synthetic peptide corresponding to the C-terminal residues 2500-2527 of human LRRK2. | |
| 100 μL | |
| Primary | |
| Human, Mouse, Bovine, C. elegans, Plant | |
| Antibody | |
| IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction